SCHEDULE 13G/A: Sio Capital Management Discloses 5.09% Stake in Aprea Therapeutics

Sio Capital Management, LLC has reported a 5.09% beneficial ownership stake in Aprea Therapeutics, Inc. as of December 31, 2024, according to an amended Schedule 13G filing.

Summary

• Sio Capital Management, LLC (the "Reporting Person"), a Delaware limited liability company and registered investment adviser, filed an Amendment No. 1 to Schedule 13G.
• The filing reports beneficial ownership of common stock in Aprea Therapeutics, Inc. (the "Issuer").
• As of December 31, 2024, Sio Capital Management, LLC beneficially owned 276,603 shares of Aprea Therapeutics, Inc. common stock.
• This ownership represents 5.09% of Aprea Therapeutics, Inc.'s common stock outstanding.
• The percentage is calculated based on 5,434,903 shares of common stock outstanding as of November 7, 2024, as reported in the Issuer's Form 10-Q filed with the SEC on that date.
• Sio Capital Management, LLC holds shared voting power and shared dispositive power over all 276,603 beneficially owned shares.
• The shares are held by certain affiliated funds for which Sio Capital Management, LLC acts as an investment adviser.
• Michael Castor, who controls Sio Capital Management, LLC and Sio GP, LLC, may be deemed to control the voting and dispositive decisions over these shares, though beneficial ownership is expressly disclaimed for purposes of Section 13(d) of the Exchange Act.

Sentiment

Score: 5

Explanation: The document is a standard beneficial ownership disclosure (Schedule 13G) and does not contain information that would typically indicate positive or negative sentiment regarding the company's operational or financial performance.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, which can influence market perception and trading activity.

Key Dates

Keywords

Aprea Therapeutics, Sio Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Institutional Investor